Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2025-12-27 @ 11:32 PM
Study NCT ID:
NCT00858234
Status:
COMPLETED
Last Update Posted:
2021-04-09
First Post:
2009-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-02-13
Start Date Type:
ACTUAL
Primary Completion Date:
2010-06-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-04-19
Completion Date Type:
ACTUAL
First Submit Date:
2009-03-04
First Submit QC Date:
None
Study First Post Date:
2009-03-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-03-04
Results First Submit QC Date:
None
Results First Post Date:
2021-04-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-07
Last Update Post Date:
2021-04-09
Last Update Post Date Type:
ACTUAL